ArticlePharmaceutics2023
Honokiol-Loaded Nanoemulsion for Glioblastoma Treatment: Statistical Optimization, Physicochemical Characterization, and an In Vitro Toxicity Assay.
Article in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 26 citations in OpenAlex.
- Development and Characterization of Intravenous Nanoemulsions Loaded withMolecules (Basel, Switzerland) · 2026Article
- Nanotechnology for efficient delivery of TCM active ingredients in treating brain diseases.Materials today. Bio · 2026Review
- Bridging the Gap in the Clinical Application of Advanced Parenteral Nutrition Formulations: From Efficacy to Real-World Challenges.Advances in nutrition (Bethesda, Md.) · 2026Review
- Nature Meets Science: The Role of Food-Grade Oils and Green Excipients in Pharmaceutical Nanoemulsion Formulation.Materials (Basel, Switzerland) · 2026Review
- Optimising Cannabidiol Delivery: Improving Water Solubility and Permeability Through Phospholipid Complexation.International journal of molecular sciences · 2025Article
- Nanotherapy of Glioblastoma-Where Hope Grows.International journal of molecular sciences · 2025Review
- Article
- Quantification of the Most Effective X-Ray Dosage for Inhibiting Invasion of Glioma Cell Line.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- New Avenues and Major Achievements in Phytocompounds Research for Glioblastoma Therapy.Molecules (Basel, Switzerland) · 2024Review
- Development and preclinical assessment of nanoemulgel loaded with phytoconstituents for the management of rheumatoid arthritis.Drug delivery and translational research · 2024Article
- Lipid Nanoparticles: An Effective Tool to Improve the Bioavailability of Nutraceuticals.International journal of molecular sciences · 2023Review
- The Development of Magnolol-Loaded Intravenous Emulsion with Low Hepatotoxic Potential.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Nanotechnology-Based Drug Delivery Systems for Honokiol: Enhancing Therapeutic Potential and Overcoming Limitations.International journal of nanomedicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
backgroundGlioblastoma (GBM) is an extremely invasive and heterogenous malignant brain tumor. Despite advances in current anticancer therapy, treatment options for glioblastoma remain limited, and tumor recurrence is inevitable. Therefore, alternative therapies or new active compounds that can be used as adjuvant therapy are needed. This study aimed to develop, optimize, and characterize honokiol-loaded nanoemulsions intended for intravenous administration in glioblastoma therapy.
methodsHonokiol-loaded nanoemulsion was developed by incorporating honokiol into Lipofundin MCT/LCT 20% using a horizontal shaker. The Box-Behnken design, coupled with response surface methodology, was used to optimize the incorporation process. The effect of the developed formulation on glioblastoma cell viability was determined using the MTT test. Long-term and short-term stress tests were performed to evaluate the effect of honokiol on the stability of the oil-in-water system and the effect of different stress factors on the stability of honokiol, respectively. Its physicochemical properties, such as MDD, PDI, ZP, OSM, pH, and loading efficiency (LE%), were determined.
resultsThe optimized honokiol-loaded nanoemulsion was characterized by an MDD of 201.4 (0.7) nm with a PDI of 0.07 (0.02) and a ZP of -28.5 (0.9) mV. The LE% of honokiol was above 95%, and pH and OSM were sufficient for intravenous administration. The developed formulation was characterized by good stability and a satisfactory toxicity effect of the glioblastoma cell lines.
conclusionsThe honokiol-loaded nanoemulsion is a promising pharmaceutical formulation for further development in the adjuvant therapy of glioblastoma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.